Reseña del libro "Non - Alcoholic Fatty Liver Disease: A Practical Guide"
Nafld: A Practical Guide 2E Will Be A Highly Practical, Clinically Focused And Accessible Book Of Approximately 350 Pages, Aimed At Consultant / Specialist Gastroenterologists And Hepatologists Who Are Treating Patients With Non - Alcoholic Fatty Liver Disease. It Will Use A Clear, Direct Layout, With Text Features Such As Iterated Key Learning Points, Bolded Key Points, Mcqs, And Will Focus On Practical, Common Issues Facing Those Treating Patients With Nafld (Including Nash), Rather Than Heavy Scientific Detail About Research Concepts And Developments. There Will Be 28 Chapters, Each One Encompassing Brief Aspects Of Disease Pathogenesis, With The Bulk Of The Chapters On The Practical Aspects Of Clinical Presentation And Diagnosis, Prevention, Patient Care And Future Perspectives. One Of Its Core Strengths Will Be To Present The Latest Information In How Nafld Relates To Other Medical Conditions Such As Obesity, Diabetes, High Cholesterol, And Liver Cancer. Given This, The Book Will Also Appeal To Endocrinologists And Cardiologists Seeing Patients With Elevated Cholesterol, Insulin Resistance, And High Levels Of Obesity. With Senior And Well - Renowned Hepatologists From The Uk, Australia And The Us Making Up The Editor Team, Nafld: A Practical Guide 2E Will Address A World Audience, With Particular Focus On North America, Europe And Asia - Pacific. To Help Achieve This International Focus, The Authors Chosen To Write Each Chapter Will Be In Roughly Equivalent Numbers From Each Of North America, Europe And Asia - Pacific. How, Where And Under What Circumstances Will This Book Be Used? It Will Be Used By Consultant / Specialist Gastroenterologists And Hepatologists (And Perhaps Fellows At The Top End Of Speciality Training) Who Are Regularly Treating Patients Presenting With Non - Alcoholic Fatty Liver Disease. It May Also Be Used By Endocrinologists And Cardiovasular Disease Specialists, Given The Close Links Between Nafld And The Conditions That These Specialists Will Regularly Encounter In Patients. If New Edition, What Has Changed From The Previous Edition (Summarise Results Of Development / Market Research If Applicable)? 4 Brand New Chapters, Including Nafld And Cardiovascular Risk Factors And Non - Invasive Methods To Determine Severity Of Nafld / Nash Inclusion Of A British Or European Hepatologist Of Good Standing, Which Will Help Raise Its Profile In Europe. Sales In Europe Were Not Particularly High Last Time Around. Less Science, More Clinical. New Edition Will Have A Revamped Contents That Is A Lot More Clinical Than Previously (Last Time Was 50% Science, This Time That Will Be 10 - 20%), With Less Focus On Pathogenesis, Epidemiology, Genetics, Animal Models And Basic Science Of Fld And More Focus On The Clinical Assessment, Diagnosis And Treatment Of The Patient In The Clinical Setting. This Will Ensure That It Appeal More To The Practicing Hepatologist Than The Research Scientist. Revamped Interior. More Attractive And User - Friendly, All Chapters Will Include Key Points, Multiple - Choice Questions To Allow Users To Self - Assess Themselves, And Recent Clinical Trials In Each Chapter. List Of Contributors, Vii 1 What Is Non - Alcoholic Fatty Liver Disease (Nafld), And Why Is It Important? 1Geoffrey C. Farrell, Arthur J. Mccullough, And Christopher P. Day 2 Nafld In The Community, 17Leon A. Adams 3 Pathology Of Nafld, 27Elizabeth M. Brunt And David E. Kleiner 4 The Natural History Of Nafld, 37Paul Angulo 5 Emerging Concepts On The Pathogenesis Of Non - Alcoholic Steatohepatitis (Nash), 46Isabelle A. Leclercq 6 Diabetes And Nafld: Why Is The Connection Important? 62Elisabetta Bugianesi 7 Nafld And Cardiovascular Risk Factors: Implications For Vascular Disease, 71Giovanni Targher 8 A Primary Care Perspective Of Fatty Liver: Diagnosis, Management, Prescribing, And When To Refer, 84Shivakumar Chitturi And Geoffrey C. Farrell 9 Imaging Of Nafld, 93Takeshi Yokoo, An Tang, And Claude B. Sirlin 10 Non - Invasive Methods To Determine The Severity Of Nafld And Nash, 112Vincent Wai - Sun Wong And Henry Lik - Yuen Chan 11 Fatigue, Quality Of Life, And Psychosocial Issues For People With Nafld, 122Julia L. Newton And James Frith 12 Physical Activity And Cardiovascular Fi Tness In Patients With Nafld: Clinical Importance And Therapeutic Implications, 132Ingrid J. Hickman, Graeme A. Macdonald, And Nuala M. Byrne 13 Nafld, Obesity, And Bariatric Surgery, 149Philippe Mathurin 14 Genetic Predisposition To Nafld And Nash: Implications For Pathogenesis, Diagnosis, Prevention, And Management, 157Quentin M. Anstee, Ann K. Daly, And Christopher P. Day 15 Nafld In Children, 171Ariel E. Feldstein 16 The Pointy End Of The Nafld Iceberg: Cirrhosis, Portal Hypertension, And Liver Failure, 182Jonathon W. Schwake, Dawn M. Torres, And Stephen A. Harrison 17 Non - Alcoholic Fatty Liver Disease, Hepatocellular Cancer, And Other Cancers, 192Janine Graham And Helen L. Reeves 18 Nafld In Chinese And South Asian People, 206Jia - Horng Kao, Deepak Amarapurkar, And Jian - Gao Fan 19 Non - Alcoholic Fatty Liver Disease In Japan, 217Takeshi Okanoue, Kohichiroh Yasui, And Yoshito Itoh 20 Non - Alcoholic Fatty Liver Disease In South America And Hispanic People, 228Helma Pinchemel Cotrim And Carla Daltro 21 Alcohol In Non - Alcoholic Fatty Liver Disease: An Oxymoron Or A New Standard Of Care?, 234Achuthan Sourianarayanane, Srinivasan Dasarathy, And Arthur J. Mccullough 22 Dietary Factors In The Pathogenesis And Care Of Patients With Fatty Liver Disease, 248Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, And Silvia Di Domizio 23 Metabolic Factors And Steatosis In Patients With Hepatitis B And C, 260Francesco Negro 24 Drug Therapy For Nash: Insulin - Sensitizing Agents (Metformin And Thiazolidinediones), 271Mohammad S. Siddiqui And Arun J. Sanyal 25 Hepatoprotectants Against Fatty Liver Disease: Antioxidants, Ursodeoxycholic Acid, And Herbal Medicines, 284Anne Catherine Bürgi And Jean - François Dufour 26 Lipid Modifiers And Nash: Statins, Ezetimibe, Fibrates, And Other Agents, 293Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, And Maurizio Cassader Index, 308 Color Plate Section Facing P86
